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Abstract: 
This paper uses management science methodology to compare the cost-effectiveness of two 
different approaches to preventing coronary heart disease in the province of New Brunswick, 
Canada. The general model utilized included realistic assumptions about implementation costs, 
effectiveness levels, budget constraints and implementation strategies. Integer linear 
programming methods were then used to examine the cost-effectiveness of the two approaches, 
as well as to compare them with a third "integrated" approach which combined elements of both 
approaches. The study concludes that under ideal circumstances, a population approach has 
greater potential to prevent CHD, and when costs were considered from a societal perspective, it 
is also the more cost-effective option. However, under more realistic outcome conditions we 
found that a high risk approach may be more effective, and when costs were considered from the 
perspective of the publicly funded health care system we found that there are conditions under 
which the high risk approach is more cost-effective. Our final conclusion is that an integrated 
approach is more cost-effective than a straight high risk approach under all conditions, and more 
cost-effective than a straight population approach in all but a few circumstances. 
 healthcare management science | cost-effectiveness analysis | integer programming Keywords: 
applications | coronary heart disease | international business 
 
Article: 
1. INTRODUCTION 
 
Cost pressures have contributed to the growing use of economic evaluation techniques to support 
health care planning and decision making. One health care area where economic evaluation is 
particularly important is the prevention of coronary heart disease (CHD), which is a leading 
cause of death and disability in much of the industrialized world. Since several of the major risk 
factors for heart disease are modifiable, it is generally accepted that CHD is largely preventable 
(Victoria Declaration on Heart Health, 1992). Recognition of the need for economic evaluation 
of CHD prevention strategies reflects both the large volume of health care resources at stake and 
the fact that a number of different approaches to reducing the health and economic burden of 
CHD have been advocated. 
 
Strategies for the prevention of CHD tend to be distinguished by their focus on interventions 
which are applied either on an individual basis or on a mass basis. Individualized intervention 
activities are generally associated with the so called high risk approach to CHD prevention since 
they involve identifying and treating individuals who are at increased risk of developing CHD 
due to factors such as high blood pressure and elevated blood cholesterol. Mass intervention 
activities, on the other hand, are more commonly classed as population approaches because they 
focus on encouraging all individuals in a population to adopt lifestyle changes which will reduce 
their risk of developing heart disease. 
 
Despite the general consensus that population-based approaches to CHD prevention are likely to 
be more cost-effective than high risk approaches (National Cholesterol Education Program, 
1988; Canadian Consensus Conference on Cholesterol: Final Report, 1988; Toronto Working 
Group on Cholesterol Policy, 1990), very little is known about the actual costs or health impact 
of implementing either type of CHD prevention strategy on a long-term, province wide basis. 
Two studies, (Boyne et. al., 1996, 2000), have examined the potential health impact and probable 
costs associated with a population-based CHD prevention strategy in New Brunswick. The 
authors tested the utility of a multivariate risk prediction model for forecasting the potential 
impact of CHD prevention strategies on future heart disease rates in New Brunswick. The results 
suggested that even at very low efficacy levels (i.e., reducing CHD risk by only 9% of the 
amount possible) population-based CHD prevention programs may be capable of achieving a 
break-even level of effectiveness. There is a lack of information, however, comparing the 
expected costs and benefits of the population approach to alternative high risk intervention 
strategies. 
 
Specifically, there are at least two aspects of research on the population-based and high risk 
approaches to CHD prevention which merit further investigation. First, the potential cost-
effectiveness of the population approach has been examined only on the basis of seemingly 
optimistic assumptions about the compliance levels likely to result from the promotion of 
lifestyle changes in large, free living populations. Second, previous cost-effectiveness research 
has typically been based on an "all or none" type of scenario in which it is assumed that decision 
makers must choose between one intervention approach or the other. In reality, however, 
decision makers may implement combinations of high risk and population intervention 
strategies, and budget or operational constraints may preclude the extension of all intervention 
activities to all target groups. 
 
1.1 CHD Prevention Strategies--The High Risk Approach 
 
High risk approaches to CHD prevention consist of some form of screening activity to identify 
"at risk" individuals in the general population, followed by individualized treatment or 
counselling interventions designed to reduce risk factor levels in these individuals. Although this 
frequently involves the use of lipid and/or blood pressure lowering medications, the high risk 
approach may also include individualized behavioural modification activities such as counselling 
or treatment for smoking cessation, dietary change and/or increased physical activity. Many 
questions remain about the overall impact that population-wide pharmacological interventions 
are likely to have on CHD rates. Of particular concern is the problem of patient compliance with 
medication regimens. It appears that an optimistic estimate of long term compliance with either 
high blood pressure or lipid lowering medications is unlikely to be greater than 50%, while a 
realistic estimate is probably considerably lower (Health Services Utilization and Research 
Commission, 1995; McCombs et. al 1994; Jones, Gorkin and Lian, 1995). 
 
1.2 CHD Prevention Strategies--The Population Approach 
 
The population approach to CHD prevention is characterised by activities such as public 
education, social marketing campaigns and community mobilization initiatives which are 
targeted at large groups and designed to promote widespread adoption of "heart healthy" 
behaviour or lifestyle changes (for a review see Shea and Basch, 1990a). Findings on the impact 
of population-based approaches to CHD prevention have been mixed and somewhat difficult to 
interpret (Puska, Salonen, Nissinen, et al., 1983; Puska, Tuomilehto, Salonen, et al., 1989; Stern, 
Farquhar, Maccoby and Russell, 1976; Farquar, Fortman, Flora, et al., 1990; McCormick and 
Skarabank, 1988; Oliver, 1983;.Shea and Basch, 1990b). These results have led reviewers to 
conclude that when implemented on a population-wide basis, heart health promotion programs 
are likely to have a more modest net effect on CHD risk than was suggested by some of the early 
community intervention trials, and that it may take periods of up to ten to fifteen years for the 
impact of healthy lifestyle changes to be reflected in reduced CHD rates (Mittlemark, Hunt, 
Heath, and Schnid, 1993). 
 
1.3 CHD Prevention Strategies--Comparison Methods 
 
In general, previous comparison methods have been unable to address two important questions 
concerning the relative cost-effectiveness of high risk and population intervention strategies. 
First, they ignore the fact that interventions do not have to be implemented in the entire 
population. Specific interventions could be targeted to those sub-segments of the population 
where they are expected to be most cost effective (Promoting Heart Health in Canada). The 
second, and perhaps more important question over looked by most previous research concerns 
the possibility that the most cost-effective strategy for preventing CHD may involve a combined 
approach in which high risk interventions are directed at some targeted groups, while population 
interventions are directed at others. 
 
2. METHOD 
 
In the present study a three stage calculation was used to compare the cost-effectiveness of high 
risk and population-based approaches. The first stage involved development of an outcome 
model designed to estimate the expected health impact of implementing a population and a high 
risk CHD prevention strategy in New Brunswick over a fifteen year period. The second stage of 
calculations was to estimate the expected costs of implementing the population and high risk 
approaches over the fifteen year intervention scenario. The final stage calculations utilized 
integer linear programming models to compare the cost-effectiveness of the population and high-
risk approaches under various assumptions about costs, available resource levels and 
implementation strategies. 
 
In all models, the population was segmented into six target groups comprised of males and 
females between the ages of 30-44, 45-59 and 60-74. In addition, for the cholesterol intervention 
activity, individuals in each age/sex group were further categorized into high and low risk 
segments based on their future risk of developing coronary heart disease. 
 
2.1 Sample 
 
The present study focused on CHD prevention in adult New Brunswickers between the ages of 
30 and 74. A stratified random sample of 1,128 subjects was derived from the 1989 New 
Brunswick Heart Health Survey (NBHHS). Details of the demographic characteristics of the 
sample are presented in (Boyne, 1997). 
 
2.2 Intervention Scenarios 
 
As previously noted, the models used to estimate the expected costs and health impact of the 
high risk and population approaches were based on a fifteen year intervention scenario. The use 
of this relatively long time period is consistent with the view that the proper development and 
implementation of a comprehensive CHD prevention program requires at least a ten year time 
frame (Promoting Heart Health in Canada) and that the full impact of such a program may not 
become evident for several additional years (Mittlemark, et al., 1993). Exposition of the many 
details of the timing assumptions used in high risk and population approach scenarios can be 
found in (Boyne, 1997). 
 
2.3 Calculation Stage 1: The Outcome Model 
 
A model was developed for calculating outcome coefficients which represent the expected 
impact of each of the five intervention activities (promotion of smoking cessation, healthy eating 
and increased physical activity; detection and pharmacological treatment of high blood pressure 
and elevated blood cholesterol) on future CHD rates in each of the target groups. A 4-step 
procedure was followed: 
 
1. Calculate expected CHD incidence in New Brunswick over a 15 year period without 
interventions. This involved using the Framingham risk prediction equations (Anderson et. al., 
1991; Kannel & Gordon, 1971). See (Boyne, 1997) and (Boyne, Bhadury and Balram, 1996) for 
details. 
 
2. Transform population parameters to match 100% compliance with intervention strategies. For 
example, if the intervention was smoking cessation then all smokers were reclassified as 
nonsmokers. 
 
3. Calculate expected CHD incidences for 100% compliance rates using the same method as in 
step 1. The difference between the first and second CHD incidence calculation provided an 
estimate of the expected number of CHD cases which could be avoided. 
 
4. Calculate expected CHD incidence assuming partial compliance with intervention strategies. 
For example, if only 10% of smokers in a particular target group were expected to respond 
positively to a smoking cessation initiative, then the number of avoidable cases associated with 
100% compliance in that target group was multiplied by 0.1. 
 
2.4 Calculation Stage 2: The Cost Model 
 
In the second stage of calculations, fixed and variable costs associated with implementation of 
the five intervention activities on a province wide basis were estimated and applied to the various 
target groups to arrive at a cost coefficient for each intervention activity in each target group. See 
(Boyne, 1997) for details. 
 
2.5 Calculation Stage 3: The Integer Linear Programming Models 
 
The outcome and cost coefficients were incorporated into a series of integer linear programming 
models. The decision variables represent all or none decisions, i.e., a target group could either be 
subjected to an intervention activity or not, but it could not be partially subjected to an 
intervention activity. 
 
2.6 High Risk Approach Model 
 
The objective function represents the expected number of new CHD cases which would be 
prevented over the 15 year intervention scenario when the BP and cholesterol intervention 
activities were implemented in the 18 different target groups. There are three sets of constraints: 
(1) total costs must not exceed the budget B , (2) no low risk segment of a target group can 
receive cholesterol intervention unless the high risk segment of that target group also receives it, 
(3) no target group can receive cholesterol intervention unless it also receives BP intervention. 
The value of B is varied to study how selected interventions depend on the total budget. 
 
Decision Variables: 
[X.sub.1] & [X.sub.2] = BP detection & treatment in 30-44 males & females 
[X.sub.3] & [X.sub.4] = BP detection & treatment in 45-59 males & females 
[X.sub.5] & [X.sub.6 = BP detection & treatment in 60-74 males & females 
[X.sub.7] & [X.sub.8] = CH detection & treatment in 30-44 high risk males & females 
[X.sub.9] & [X.sub.10] = CH detection & treatment in 45-59 high risk males & females 
[X.sub.11] & [X.sub.12] = CH detection & treatment in 60-74 high risk males & females 
[X.sub.13] through [X.sub.18] = Same as [X.sub.7] through [X.sub.12], but for low risk 
individuals 
 
Objective Function (maximize): (22.3[X.sub.1] + 6.9[X.sub.2] + 141.83[X.sub.3] + 
28.65[X.sub.4] + 78.96[X.sub.5] + 61.2[X.sub.6] + 3.96[X.sub.7] + 2.64[X.sub.8] + 55[X.sub.9] 
+ 13.91[X.sub.10] + 85.53[X.sub.11] + 18.53[X.sub.12] + 13.09[X.sub.13] + 4.5[X.sub.14] + 
44.34[X.sub.15] + 51.38[X.sub.16] + 9.73[X.sub.17] + 72.35[X.sub.18]) 
 
Cost constraint: (1.96[X.sub.1] + 1.21[X.sub.2] + 4.57[X.sub.3] + 1.56[X.sub.4] + 1.99[X.sub.5] 
+ 2.28[X.sub.6] + .15[X.sub.7] + .31[X.sub.8] + 1.26[X.sub.9] + .67[X.sub.10] + 7[X.sub.11] + 
3.23[X.sub.12] + 1.44[X.sub.13] + 1.35[X.sub.14] +1.51[X.sub.15] + 1.91[X.sub.16] + 
.98[X.sub.17] + 10.[X.sub.18]) <= B 
 
Operational constraints 
i) [X.sub.n+6]-[X.sub.n] <= 0 , n = 7, ... 12 
ii) [X.sub.n+6]-[X.sub.n] <= 0 , n = 1, ... 6 
iii) [X.sub.n+12]-[X.sub.n] <= 0 , n = 1, ... 6 
Binary restrictions: [X.sub.1] through [X.sub.18] = 0 or 1 
 
2.7 Population Approach Model 
 
The basic population model has eighteen decision variables, each representing a different target 
group by intervention activity component. Each of 3 intervention activities was represented by 
six decision variables corresponding to the implementation of that activity in each of the age (30-
44, 45-59 and 60-74) and gender combinations. 
 
The objective function represents the expected number of new CHD cases which would be 
avoided when different intervention activities are implemented in different target groups. 
 
The population approach model has only one constraint: total costs must not exceed the budget B 
. The value of B is varied to study how selected interventions depend on the total budget. 
 
Decision Variables: 
[X.sub.1] & [X.sub.2] = smoking cessation in 30-44 males & females 
[X.sub.3] & [X.sub.4] = smoking cessation in 45-59 males & females 
[X.sub.5] & [X.sub.6] = smoking cessation in 60-74 males & females 
[X.sub.7] through [X.sub.12] = same as [X.sub.1] through [X.sub.6], but for increased physical 
activity 
[X.sub.13] through [X.sub.18] = same as [X.sub.1] through [X.sub.6], but for dietary change 
 
Objective Function (maximize): (37.45[X.sub.1] +28.17[X.sub.2] + 80[X.sub.3] + 26[X.sub.4] + 
91.3[X.sub.5] + 51.3[X.sub.6] + 27.7[X.sub.7] + 16.7[X.sub.8] + 21.9[X.sub.9] + 33.9[X.sub.10] 
+ 16.8[X.sub.11] + 29.16[X.sub.12] + 8.2[X.sub.13] + 2.2[X.sub.14] + 10.9[X.sub.15] + 
6.8[X.sub.16] + 14.8[X.sub.17] + 6.5[X.sub.18]) 
 
Cost constraint (in $ millions at the $2 fixed cost level): (2.92[X.sub.1] + 2.99[X.sub.2] + 
1.63[X.sub.3] + 1.75[X.sub.4] + 0.93[X.sub.5] + 1.13[X.sub.6] + 2.9[X.sub.7] + 2.91[X.sub.11] 
+ .1.65[X.sub.9] + 1.77[X.sub.10] +1.02[X.sub.11] + 1.40[X.sub.12] + 3.02[X.sub.13] + 
2.97[X.sub.14] +1.75[X.sub.15] + 1.89[X.sub.16] + 0.97[X.sub.17] + 1.22[X.sub.18] ) < = B 
 
Binary restrictions: [X.sub.1] through [X.sub.18] = 0 or 1 
 
2.8 Integrated Model 
 
In addition to the separate population and high risk models, an integrated model was also 
developed. The combined model includes 36 decision variables (18 from the high risk model and 
18 from the population model) representing the implementation of each intervention activity in 
each of their respective target groups. The objective function for the integrated model is simply 
the sum of the objective functions for the high risk and population models. The left side of the 
cost constraint equation in the combined model is the sum of the left sides of the budget 
constraints of the high risk and population models. The combined model also incorporates the 
two sets of operational constraints from the high risk model, and the binary restrictions. 
 
3. RESULTS AND DISCUSSION 
 
3.1 Base CHD Incidence Estimate 
 
Table 1 presents a breakdown of the number of new CHD cases predicted in the New Brunswick 
population over a fifteen year period, based on the risk factor profile of the 1989 sample. These 
assume the absence of any type of intervention program and therefore provide the base rates used 
to calculate outcome coefficients for the high risk and population-based intervention activities. 
The data in Table 1 are consistent with the existing fragmentary evidence of incidence rates in 
the New Brunswick population (Boyne, 1997). 
 
3.2 Expected Impact Under Conservative Compliance Assumptions 
 
Table 2, presents the expected actual impact of the various intervention activities on CHD 
incidence, after adjustment for the expected compliance rate of each intervention activity in each 
target group. The figures in the % P column are the estimated compliance rates for each 
intervention activity in each target group. The figures in the % T column the expected percentage 
reductions of CHD incident rates as presented in Table 1. 
 
Notice in Table 2 that the low compliance rate of the population treatments cause the overall 
expected impact of the population approach to be less than the expected actual impact of the high 
risk approach for both men and women. However, in the youngest age group the population 
approach is still expected to be more effective in reducing CHD incidence than the high risk 
approach. Another important issue with respect to the results in Table 2 concerns the validity of 
the expected compliance rates used in the present simulation. For the high blood pressure and 
cholesterol interventions, the average compliance rates are in the range of 34% to 38%. These 
compliance levels are consistent with conservative estimates of medication compliance in the 
literature and appear to provide a solid basis for calculating the expected impact of the 
pharmacological based interventions on CHD incidence. The compliance rates for the 
population-based interventions were, to the extent possible, based on survey data which 
specifically addressed lifestyle change attempts. However, it is difficult to establish the validity 
of these estimates, since there has been very little research on long term compliance with 
population-based lifestyle change interventions. See (Boyne, 1997) for details. 
 
3.3 Costs and Cost-Effectiveness 
 
Tables 3a and 3b present the estimated fifteen year costs and cost-effectiveness ratios for the 
high risk and population-based intervention activities when all costs are considered. These cost 
estimates are adjusted for anticipated compliance and therefore represent the expected cost of 
achieving the impact levels described in Table 2. The cost-effectiveness ratio equals the total 
cost (in millions of dollars) of each intervention component divided by the number of cases 
expected to be prevented by implementation of each intervention component. Therefore, lower 
cost-effectiveness ratios indicated more cost-effective intervention components. In the next 
section we describe an optimization model that directs intervention towards the most cost-
effective components. 
 
Comparisons of the cost-effectiveness ratios for the high risk and population-based approaches 
show that from a total cost perspective the population approach (the last two rows of each table) 
is clearly more cost effective in each target group. However, there are intervention components 
of the high-risk approach that have better cost-effectiveness ratios than some of the population-
based components. For example, the data suggest that detection and treatment of high blood 
pressure in 60-74 year olds is a more cost-effective means of preventing CHD than any lifestyle 
intervention in 30-44 year olds or dietary intervention in any age group. 
 
3.4 Integer Linear Programming Model Comparisons 
 
The comparisons associated with Tables 3a and 3b indicated that given full implementation the 
population approach is likely to be more cost- effective than the high risk approach. The 
objective of the linear programming stage of the calculations was to identify the combination of 
intervention components in each scenario (i.e., high risk and population-based intervention 
scenarios) which would prevent the greatest number of cases at specified spending levels. That 
is, the integer linear programs were used to identify the "optimum" combination of intervention 
components at each spending level. The calculations show that an intervention approach which 
combines both high risk and population-based intervention components will be more cost 
effective than a straight high risk approach at all spending levels, and superior to a straight 
population approach at all but very low annual spending levels. The relatively low annual 
funding levels at which the integrated approach is expected to become more cost-effective than 
the straight population approach indicates that some high risk intervention components become 
part of the optimal integrated approach well before all population-based intervention components 
have been incorporated. 
 
To examine the order in which intervention components are likely to become part of an optimal 
integrated approach, Table 4 lists the intervention components in the integrated approach 
according to the annual spending level at which they first enter the optimal solution for the 
integrated model. Table 4 also provides the CE ratio for each intervention activity. As shown in 
Table 4, the order in which the intervention components entered the optimal solution for the 
integrated approach was not determined purely by the cost-effectiveness ratio of the individual 
intervention components. For example, although increasing physical activity in 60-74 year old 
males has a CE ratio of .08 it entered the optimal solution for the integrated approach prior to 
intervention components such as HBP detection and treatment in 45 59 year old males which has 
a significantly better CE ratio (.03). The reason for this is that for some high risk intervention 
components the entry order is also influenced by the operational constraints which were built 
into the integer linear programming model. 
 
The results in Table 4 show that at the lower annual spending levels (i.e., under $.5 million/year) 
the optimal integrated approach consists primarily of lifestyle change interventions in the two 
older age groups. The one exception to this pattern is HBP deception and treatment in 60-74 year 
old males. The next distinctive grouping of intervention components to enter the optimal solution 
for the integrated approach consists of high risk plus physical activity and smoking interventions 
in 45-59 year olds, as well as HBP detection and treatment in 60-74 year old females. However, 
high blood pressure detection and treatment and smoking cessation in 30-44 year old females do 
not enter the optimal solution until the budget is about of $2.8 million. 
 
Interventions which focus on reducing smoking and increasing physical activity in the older 
segments of the target population may be highly cost-effective methods reducing CHD 
incidence. This finding is of interest, because lifestyle change interventions are often targeted 
primarily at younger segments of the population. However, the present findings clearly suggest 
that the promotion of smoking cessation and increased physical activity in older target groups, 
and in particular older women, is likely to be more cost-effective than promoting these types of 
lifestyle changes in younger target groups. The favorable cost-effectiveness ratios associated 
with these lifestyle changes in the 60-74 year age group may to some extent be attributable to the 
fact that individuals in this age group are likely to have a higher overall risk of developing CHD, 
so that even a small reduction in their relatively high risk level may have a greater impact on 
CHD incidence than a similar reduction in the lower overall risk levels of younger individuals. 
 
A second interesting point highlighted in Table 4 is that detection and treatment of both high 
blood pressure and high blood cholesterol in the 45-59 year age category, as well as detection 
and treatment of high blood pressure in 60-74 year olds are likely to be more cost-effective CHD 
prevention strategies than any population-based intervention in 30-44 year olds. This observation 
helps to explain why the integrated approach is considerably more cost-effective than the straight 
population approach at total spending levels greater than $.5 million per year, and reinforces the 
notion that an effective CHD prevention strategy must incorporate both high risk and population 
based intervention strategies. 
 
A third point worth noting, with respect to Table 4, is that up to an annual spending level of 
approximately $1.8 million (or approximately $4.5 per capita/year) all of the intervention 
activities in the optimal integrated approach are restricted to the two older age groups, and that 
even when intervention activities in the youngest age group begin to enter the optimal solution 
(beginning at an annual spending level of $1.89 million for males and $2.81 million for females), 
the first intervention components to enter are the high risk interventions rather than population-
based interventions. 
 
While the present results certainly are not intended to provide a definitive ranking of the order in 
which different intervention components should be implemented in CHD prevention programs, 
they do provide a general framework for understanding how assumptions about spending levels, 
costs and the expected impact of different intervention strategies may influence planners' 
choices. Furthermore, the present results explicitly demonstrate the importance of appropriately 
matching intervention activities with target groups in order to achieve the most cost-effective 
CHD prevention programs. 
 
4. CONCLUSIONS AND LIMITATIONS 
 
The most interesting findings from the present research emerged not from comparisons of the 
high risk and population approaches, but rather from the development and assessment of an 
"integrated" approach scenario which incorporated elements of both of the basic approaches. 
Comparisons of the integrated approach with the population and high risk approaches showed 
that the integrated approach was always expected to be more cost-effective than the high risk 
approach and was expected to become more cost-effective than the population approach at 
surprisingly low total funding levels. The relatively early stage at which the integrated approach 
was expected to become more cost-effective than the population approach indicated that certain 
high risk intervention strategies may become part of an optimal CHD prevention strategy well 
before all potential population-based intervention strategies have been fully implemented. 
 
Like all cost-effectiveness studies, the present research has a number of significant limitations. 
First, the cost estimates employed and in particular those associated with the population 
approach are imprecise and subject to future changes. Further research will be necessary to better 
define the nature and timing of input resource flows associated with the high risk and population 
approaches as well as to determine of whether these differences are likely to have a substantial 
impact on the relative cost-effectiveness of the two approaches. A second limitation of the 
present study concerns the compliance levels used to estimate the expected impact of the 
different intervention strategies. In the present research the use of conservative compliance levels 
resulted in expected health impacts which (at least in the case of the population approach) are 
considerably lower than would be expected on the basis of previous research. However, it is 
important to point out that there has been extremely little research on long term compliance with 
voluntary lifestyle changes in free living populations. Further research is needed to better define 
both the level of compliance that may be expected in population-based health promotion 
initiatives as well as the factors that may contribute to compliance. 
 
Despite its limitations, the present research has a number of practical implications for health care 
planners and decision makers. The present research shows that a simple dichotomy between high 
risk and population-based approaches is not likely to provide an adequate basis for planning and 
implementing a successful CHD prevention initiative. In addition to providing useful information 
for program planning purposes, the present study has also demonstrated the utility of employing 
integer linear programming techniques to enhance cost-effectiveness evaluation. As a result it 
was possible to conduct analyses which reveal the potential cost-effectiveness of an integrated 
approach to CHD prevention. In addition, the integer linear programs were very useful in 
identifying the order in which different intervention components should be implemented in order 
to achieve optimal program effectiveness, given a specific set of budget and operational 
constraints. The integer linear programming techniques used in the present research greatly 
expand the range and complexity of information that can be considered in cost-effectiveness 
evaluations. Although the present research focused on a single disease, it is clear that these 
techniques could be applied to cost-effectiveness research in a wide range of public health 
applications. 
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TABLE 1: PREDICTED 15-YEAR CHD INCIDENCE IN THE NEW 
BRUNSWICK POPULATION 
                      Age Group 
            30-44    45-59    60-74    30-74 
Males       5409     9060     8866    23335 
Females     1621     5290     6038    12949 
Total       7030    14350    14904    36284 
 
TABLE 2: EXPECTED COMPLIANCE RATES AND EXPECTED % REDUCTION IN 
CHD INCIDENCE 
                                  Age Group 
    Activity         Sex     30-44          45-59 
 
                            % P    % T    % P    % T 
 Blood Pressure    M     15    0.41    47    1.57 
                F     16    0.43    21    0.55 
   Cholesterol        M     13    0.31    33    1.09 
                       F     29    0.43    43    1.23 
 Total High Risk     M     14    0.72    40    2.66 
                       F     21    0.86    33    1.49 
     Smoking   M     6     0.70    10    0.88 
                      F     9     1.73    5     0.49 
      Diet          M     7     0.15    8     0.12 
                       F     10    0.12    8     0.13 
Physical Activity     M     9     0.52    5     0.24 
                    F     13    1.05    10    0.64 
Total Population    M     7     1.37    8     1.25 
                       F     10    2.90    7     1.27 
 
                                  Age Group 
 
    Activity        Sex       60-74         Total 
                         % P    % T    % P    % T 
 Blood Pressure       M     41    0.89    38    1.04 
                       F     63    1.01    35    0.75 
   Cholesterol        M     35    1.07    30    0.90 
                   F     41    1.51    41    1.26 
 Total High Risk     M     37    1.96    34    1.95 
                       F     48    2.52    38    2.01 
     Smoking          M     19    1.03    11    0.90 
                      F     17    0.84    9     0.81 
      Diet            M     12    0.17    10    0.15 
                    F     13    0.12    10    0.12 
Physical Activity     M     5     0.19    6     0.29 
                    F     8     0.48    10    0.62 
Total Population      M     13    1.39    9     1.33 
                      F     12    1.44    9     1.55 
 
TABLE 3A: EXPECTED TOTAL COST ($MILLIONS) & CE RATIOS OF HIGH RISK 
INTERVENTIONS 
 
                                   Age Group 
   Activity      Sex              30-44           45-59 
                         Total    CE     Total    CE 
                        Cost    Ratio   Cost    Ratio 
                    M      3     0.14     9.3    0.07 
Blood Pressure 
                    F     1.7    0.24     2.9    0.10 
                    M     4.8    0.28    13.9    0.14 
 Cholesterol 
                    F     4.6    0.66    10.4    0.16 
    Total           M     7.8    0.20    23.2    0.10 
Pharmaceutical     F     6.3    0.45    13.3    0.14 
 
                                 Age Group 
 
   Activity      Sex              60-74           30-74 
                      Total    CE     Total    CE 
                      Cost    Ratio   Cost    Ratio 
 
                    M     2.6    0.03    14.9    0.06 
Blood Pressure 
                    F     2.6    0.04     7.2    0.07 
                    M    12.1    0.13    30.8    0.15 
 Cholesterol 
                  F    14.6    0.16    29.6    0.18 
    Total           M    14.7    0.08    45.7    0.10 
Pharmaceutical     F    17.2    0.11    36.8    0.14 
 
TABLE 3B: EXPECTED TOTAL COST ($MILLIONS) & CE RATIO OF 
POPULATION-BASED INTERVENTIONS 
 
                                    Age Group 
 
Activity            Sex       30-44              45-59 
 
                         Total    CE     Total    CE 
                         Cost    Ratio   Cost    Ratio 
Smoking        M     2.9    0.08     1.6    0.02 
                       F      3     0.11     1.8    0.07 
Diet                  M      3     0.38     1.8    0.16 
                      F      3     1.50     1.9    0.27 
Physical Activity    M      3     0.11     1.7    0.08 
                    F      3     0.18     1.8    0.05 
Total Population-     M     8.9    0.12     5.1    0.05 
Based                 F      9     0.19     5.5    0.08 
 
                                    Age Group 
Activity            Sex       60-74           30-74 
 
                     Total    CE     Total    CE 
                      Cost    Ratio   Cost    Ratio 
Smoking                  M     0.9    0.01     5.4    0.03 
                          F     1.1    0.02     5.9    0.06 
Diet                       M      1     0.07     5.8    0.17 
                              F     1.2    0.17     6.1    0.38 
Physical Activity    M     1.4    0.08     6.1    0.09 
                             F     0.9    0.03     5.7    0.07 
Total Population-    M     3.3    0.03    17.3    0.06 
Based                F     3.2    0.04    17.7    0.09 
 
TABLE 4: INTERVENTION COMPONENTS RANKED BY ORDER OF ENTRY INTO 
OPTIMAL SET 
 
        Intervention Component (CE Ratio) 
 
Entry                 30-44 
Level 
              Male              Female 
 
 .03 
 .13 
 .14 
 .17 
 .23 
 .30 
 .37 
 .53 
 .55 
 .74 
 1.2 
1.69 
 1.8 
1.89       HBP (.10) 
        [CH.sup.1] (.04) 
1.93      Smoking .08) 
2.18    [CH.sup.2] (.11) 
2.19     Activity (.09) 
2.25 
2.33 
 2.8                          HBP (.17) 
                            Smoking (.11) 
3.27 
3.32                       [CH.sup.1] (.11) 
3.42                        Activity (.18) 
3.54 
3.81 
4.64 
 4.8       Diet (.38) 
5.02                       [CH.sup.2] (.30) 
5.48                          Diet (1.5) 
 
        Intervention Component (CE Ratio) 
 
Entry                 30-44 
Level 
              Male              Female 
 
 .03 
 .13 
 .14 
 .17     Smoking (.02) 
 .23 
 .30 
 .37                        Activity (.05) 
 .53    [CH.sup.1] (.02)      HBP (.06) 
                           [CH.sup.1] (.05) 
 .55       HBP (.03) 
 .74    [CH.sup.2] (.03) 
 1.2                       [CH.sup.2] (.03) 
1.69                        Smoking (.07) 
 1.8     Activity (.08) 
1.89 
1.93 
2.18 
2.19 
2.25 
2.33 
 2.8 
3.27       Diet (.16) 
3.32 
3.42 
3.54 
3.81 
4.64                          Diet (.27) 
 4.8 
5.02 
5.48 
 
        Intervention Component (CE Ratio) 
 
Entry                 30-44 
Level 
              Male              Female 
 
 .03     Smoking (.01) 
 .13     Activity (.08) 
 .14                        Smoking (.02) 
 .17 
 .23                        Activity (.03) 
 .30       HBP (.03) 
 .37       Diet (.07) 
 .53                          HBP (.04) 
 .55 
 .74 
 1.2 
1.69 
 1.8 
1.89 
1.93 
2.18 
2.19 
2.25    [CH.sup.1] (.09) 
2.33    [CH.sup.2] (.10) 
 2.8 
3.27 
3.32 
3.42                          Diet (.17) 
3.54                       [CH.sup.1] (.17) 
3.81                       [CH.sup.2] (.14) 
4.64 
 4.8 
5.02 
5.48 
 
[CH.sup.1] = Detection and treatment of elevated blood cholesterol levels in high risk 
individuals. 
 
[CH.sup.2] = Detection and treatment of elevated blood cholesterol levels in low risk individuals. 
 
The results in Table 4 highlight several interesting points. First, these results show that 
population-based 
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